journal
MENU ▼
Read by QxMD icon Read
search

Asia-Pacific Journal of Clinical Oncology

journal
https://www.readbyqxmd.com/read/28304150/additional-chemotherapy-and-salvage-surgery-for-poor-response-to-chemoradiotherapy-in-rectal-cancers
#1
Reena Engineer, Vikas Ostwal, Supreeta Arya, Priyamvada Gupta, Supriya Chopra, Prachi Patil, Sudhir Jatal, Avanish Saklani
AIM: A proportion of locally advanced rectal cancer patients who receive neoadjuvant chemoradiotherapy (NACRT) are still unresectable. This study was undertaken to assess the outcomes of giving additional chemotherapy to rectal cancer patients with unresectable disease after NACRT. METHODS: Patients with poor response to NACRT where mesorectal fascia was still involved on MRI and R0 resection was doubtful, received additional four cycles of chemotherapy with either CAPOX or FOLFIRINOX regimen, and the response was reevaluated with MRI and reassessed for surgical resection...
March 17, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28303657/what-does-it-cost-medicare-to-diagnose-and-treat-men-with-localized-prostate-cancer-in-the-first-year
#2
Merehau C Mervin, Anthony Lowe, Robert A Gardiner, David P Smith, Joanne Aitken, Suzanne K Chambers, Louisa G Gordon
OBJECTIVE: To estimate costs on the Medicare Benefits Schedule (MBS) and the Pharmaceutical Benefits Scheme (PBS) attributable to the diagnosis and treatment of prostate cancer. METHODS: We used data from a cohort study of 1064 men with localized prostate cancer recruited between 2005 and 2007 by 24 urologists across 10 sites in Queensland, Australia (ProsCan). We estimated the MBS and PBS costs attributable to prostate cancer from the date of initial appointment to 12 months after diagnosis in 2013 Australian dollars using a comparison group without prostate cancer...
March 16, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28303646/quality-of-life-on-tsu-68-combination-of-docetaxel-and-tsu-68-an-oral-antiangiogenic-agent-in-patients-with-metastatic-breast-cancer-previously-treated-with-anthracycline
#3
Byeong Seok Sohn, Sung-Bae Kim, Jin-Hee Ahn, Kyung Hae Jung, Jeongeun Kim, Keun Seok Lee, Jungsil Ro, Seock-Ah Im, Young-Hyuck Im, Hong Suk Song, Hee Sook Park, Hyun-Cheol Chung
AIM: The aim of this study is to investigate whether the addition of TSU-68 would affect on the quality of life (QOL) of Korean metastatic breast cancer patients treated with docetaxel. METHODS: Sixty-three of 78 patients completed the baseline QOL questionnaires and at least one follow-up questionnaire comprising questions from the Korean Functional Assessment of Cancer Therapy-Breast (FACT-B), hospital anxiety and depression scale (HAD), the shortened form of the profile of mood states (BPOMS), and anticipation and anxiety for treatment scale...
March 16, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28299879/how-accurate-are-medical-oncologists-impressions-of-management-of-metastatic-colorectal-cancer-in-australia
#4
Lewis Au, Natalie Turner, Hui-Li Wong, Kathryn Field, Belinda Lee, David Boadle, Prasad Cooray, Deme Karikios, Suzanne Kosmider, Lara Lipton, Louise Nott, Phillip Parente, Jeanne Tie, Ben Tran, Rachel Wong, Desmond Yip, Jeremy Shapiro, Peter Gibbs
AIM: Current efforts to understand patient management in clinical practice are largely based on clinician surveys with uncertain reliability. The TRACC (Treatment of Recurrent and Advanced Colorectal Cancer) database is a multisite registry collecting comprehensive treatment and outcome data on consecutive metastatic colorectal cancer (mCRC) patients at multiple sites across Australia. This study aims to determine the accuracy of oncologists' impressions of real-word practice by comparing clinicians' estimates to data captured by TRACC...
March 16, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28296233/sustained-response-to-standard-dose-osimertinib-in-a-patient-with-plasma-t790m-positive-leptomeningeal-metastases-from-primary-lung-adenocarcinoma
#5
Oscar Siu-Hong Chan, Warren Kam-Wing Leung, Rebecca Mei-Wan Yeung
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation. After 23 months of treatment with gefitinib, intercalated with multiple courses of radiotherapy, leptomeningeal metastases (LMs) developed. Acquired T790M mutation was confirmed by the droplet digital polymerase chain reaction plasma EGFR test. After switching to osimertinib at the standard dose, his neurocognitive function improved clinically, coupled with sustained radiological improvement...
March 15, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28296250/different-genetic-alteration-of-a20-in-a-s%C3%A3-zary-syndrome-case-with-v%C3%AE-2-j%C3%AE-22-t-cell-clone
#6
Lingling Zhou, Haitao Zheng, Xin Huang, Lihua Zhu, Suijing Wu, Chengwu Zeng, Lijian Yang, Shaohua Chen, Gengxin Luo, Xin Du, Yangqiu Li
BACKGROUND: The comprehensive genetic alterations underlying the pathogenesis of Sézary syndrome (SS) remains largely unknown. Previous studies showed that alterations of tumor necrosis factor-α-induced protein 3 gene (TNFAIP3; A20) are frequent in SS. In this study, we characterized the mutation and polymorphisms of A20 in a case with SS and compared with the genetic feature of A20 in T-cell acute lymphoblastic leukemia (T-ALL). METHODS: Using a novel approach based on the combination of fine-tiling array comparative genomic hybridization ( and ligation-mediated polymerase chain reaction (LM-PCR) to identify SS clone, the polymorphisms in the A20 gene (promoter, exons 2-9 [coding region] and 3'UTR) were detected by PCR and sequencing...
March 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28294576/end-of-life-care-where-do-cancer-patients-want-to-die-a-systematic-review
#7
REVIEW
Jonas Nilsson, Carl Blomberg, Georg Holgersson, Tobias Carlsson, Michael Bergqvist, Stefan Bergström
The importance to die at preferred death place is substantial among terminally ill cancer patients. Previously, several studies have investigated this issue, but no systematic review has been made for many years. This systematic review was made in order to investigate preferred death place among cancer patients. A systematic search was made in PubMed library and a total of 399 articles were found, of which 23 were eligible and included in the review. Preference of home death averaged by 59.9% (39.7-100%) across all studies...
March 13, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28276170/pre-treatment-serum-lactate-dehydrogenase-as-a-biomarker-in-small-cell-lung-cancer
#8
Amy Hsin-Chieh Hsieh, Harminder Tahkar, Bogda Koczwara, Ganessan Kichenadasse, Kerri Beckmann, Christos Karapetis, Shawgi Sukumaran
BACKGROUND: Small cell lung cancer is a rapidly progressive disease with high fatality. No sensitive and specific biomarker to assist in managing this disease exists currently. AIM: Role of pretreatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. METHODS: A hospital-based cancer registry was used to identify eligible patients from 1999 to 2009. Demographic data, lactate dehydrogenase level and clinical outcome of patients were collected for analysis...
March 8, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28276163/efficacy-of-icotinib-in-lung-squamous-cell-cancer-a-real-world-experience-from-single-institution
#9
Jianping Xu, Xiaoyan Liu, Sheng Yang, Xiangru Zhang, Yuankai Shi
AIM: Squamous cell carcinoma is a less common type of nonsmall cell lung cancer (NSCLC) which associates with a poor clinical prognosis and lacks specific therapy. This study aimed to evaluate the efficacy and safety of icotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has proven to be effective in EGFR-mutated NSCLC, in patients with lung squamous-cell cancer. METHODS: Retrospective analysis was conducted in patients who had advanced lung squamous-cell cancer confirmed by cytology or histology...
March 8, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28198155/sunrise-in-melanoma-management-time-to-focus-on-melanoma-burden-in-asia
#10
John Wen-Cheng Chang, Jun Guo, Chia-Yen Hung, Si Lu, Sang Joon Shin, Richard Quek, Anthony Ying, Gwo Fuang Ho, Huu Sau Nguyen, Boman Dhabhar, Virote Sriuranpong, Maria Luisa Tiambeng, Nugroho Prayogo, Naoya Yamazaki
No abstract text is available yet for this article.
February 15, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28181415/a-phase-ii-trial-of-concurrent-chemotherapy-with-intravenous-cisplatin-and-vinorelbine-and-radiotherapy-followed-by-consolidation-chemotherapy-with-oral-vinorelbine-in-locally-advanced-non-small-cell-lung-cancer-nsclc-the-concave-study
#11
Brett Gm Hughes, Elizabeth Ahern, Margot Lehman, Gary Pratt, Margaret Dauth, Wendy Pritchard, Leesa Wockner, Keith Horwood
AIM: Despite recent advances, outcomes for patients with stage III non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy (CRT) remain poor. We evaluated the combination of ciplatin/vinorelbine and concurrent thoracic radiotherapy followed by consolidation oral vinorelbine in this phase II study. METHODS: Eligible patients with unresectable stage III NSCLC received cisplatin intravenous (IV) 40 mg/m(2) and vinorelbine IV 20 mg/m(2) on days 1, 8, 22 and 29 concurrent with thoracic radiotherapy of 60 Gy in 30 fractions...
February 9, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28181405/epidemiology-of-breast-cancer-in-indian-women
#12
REVIEW
Shreshtha Malvia, Sarangadhara Appalaraju Bagadi, Uma S Dubey, Sunita Saxena
Breast cancer has ranked number one cancer among Indian females with age adjusted rate as high as 25.8 per 100,000 women and mortality 12.7 per 100,000 women. Data reports from various latest national cancer registries were compared for incidence, mortality rates. The age adjusted incidence rate of carcinoma of the breast was found as high as 41 per 100,000 women for Delhi, followed by Chennai (37.9), Bangalore (34.4) and Thiruvananthapuram District (33.7). A statistically significant increase in age adjusted rate over time (1982-2014) in all the PBCRs namely Bangalore (annual percentage change: 2...
February 9, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28124437/presence-of-pleural-effusion-is-associated-with-a-poor-prognosis-in-patients-with-epidermal-growth-factor-receptor-mutated-lung-cancer-receiving-tyrosine-kinase-inhibitors-as-first-line-treatment
#13
Tso-Fu Wang, Sung-Chao Chu, Jen-Jyh Lee, Gee-Gwo Yang, Wei-Han Huang, En-Ting Chang, Tissot Low, Yi-Feng Wu, Ruey-Ho Kao, Chih-Bin Lin
AIM: This study was conducted to evaluate the effect of clinical factors on the treatment outcomes of lung cancer patients with active epidermal growth factor receptor (EGFR) mutations treated by first-line tyrosine kinase inhibitors (TKIs). METHODS: Patients of stage IIIb or IV lung adenocarcinoma harboring mutated EGFR were enrolled between March 2010 and June 2014 and followed up until December 2015. The effects of various clinical features, such as age, sex, smoking history, EGFR mutation types, TKIs used, presence of pleural effusion, metastatic sites on progression-free survival (PFS) and overall survival (OS), were analyzed retrospectively...
January 26, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28124500/efficacy-safety-and-pharmacokinetics-of-subcutaneous-azacitidine-in-taiwanese-patients-with-higher-risk-myelodysplastic-syndromes
#14
Wen-Chien Chou, Su-Peng Yeh, Liang-Tsai Hsiao, Sheng-Fung Lin, Yeu-Chin Chen, Tsai-Yun Chen, Eric Laille, Anoula Galettis, Qian Dong, Steve Songer, C L Beach
AIM: Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were established in mainly Caucasian populations. Because of inter-ethnic genotype variability of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. METHODS: In this single-arm study, Taiwanese patients with higher-risk myelodysplastic syndromes received azacitidine 75 mg/m(2) /day for 7 days/28-day cycle for up to six cycles...
January 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28124495/very-high-risk-prostate-cancer-stratification-by-outcomes-of-radiotherapy-and-long-term-androgen-deprivation-therapy
#15
Natsuo Tomita, Norihito Soga, Yuji Ogura, Takumi Kageyama, Takeshi Kodaira
AIM: The definition of very high-risk (VHR) prostate cancer is currently based on the study of radical prostatectomy. We aimed to identify a suitable definition for VHR group following external beam radiation therapy (EBRT) and long-term androgen-deprivation therapy (ADT). METHODS: This retrospective study included 356 high-risk patients treated with EBRT and long-term ADT. A median follow-up time was 68 months. At first, associations of previously described prognostic factors with biochemical disease-free survival (bDFS), clinical relapse-free survival (cRFS) and prostate cancer-specific survival (CSS) were examined...
January 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28120376/administrative-data-provide-vital-research-evidence-for-maximizing-health-system-performance-and-outcomes
#16
David Roder, Elizabeth Buckley
Although the quality of administrative data is frequently questioned, these data are vital for health-services evaluation and complement data from trials, other research studies and registries for research. Trials generally provide the strongest evidence of outcomes in research settings but results may not apply in many service environments. High-quality observational research has a complementary role where trials are not applicable and for assessing whether trial results apply to groups excluded from trials...
January 24, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28101911/comparison-of-cbv-beam-and-beac-high-dose-chemotherapy-followed-by-autologous-hematopoietic-stem-cell-transplantation-in-non-hodgkin-lymphoma-efficacy-and-toxicity
#17
Youwu Shi, Peng Liu, Shengyu Zhou, Jianliang Yang, Xiaohong Han, Xiaohui He, Changgong Zhang, Lin Gui, Yan Qin, Sheng Yang, Liya Zhao, Jiarui Yao, Bo Jia, Shuxiang Zhang, Yan Sun, Yuankai Shi
AIM: Limited data are available to guide the choice of conditioning regimen before autologous hematopoietic stem cell transplantation (AHSCT) for patients with lymphoma. METHODS: We analyzed 129 non-Hodgkin lymphoma patients who underwent AHSCT from 1996 to 2013 using the most common regimens: CBV (cyclophosphamide, carmustine and etoposide; n = 16), BEAM (carmustine, etoposide, cytarabine and melphalan; n = 36) and BEAC (carmustine, etoposide, cytarabine and cyclophosphamide; n = 77)...
January 19, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28078806/prognostic-factors-of-hepatocellular-carcinoma-patients-with-portal-vein-tumor-thrombosis-treated-with-transcatheter-arterial-chemoembolization
#18
Hongyuan Liang, Peng Cui, Qiyong Guo, Xiaonan Mao, Feng Wen, Wei Sun, Ming Shan, Zaiming Lu
AIM: To investigate the factors that influence survival of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) following transarterial chemoembolization (TACE). METHODS: Retrospectively enrolled HCC patients with PVTT (n = 57). Patients received TACE, and the local tumor response was evaluated by modified response evaluation criteria in solid tumor (mRECIST). Overall survival and disease progression were evaluated using Kaplan-Meier survival curves...
January 12, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28134505/china-experts-consensus-on-the-diagnosis-and-treatment-of-advanced-stage-primary-lung-cancer-2016-version
#19
Yuankai Shi, Yan Sun, Jinming Yu, Cuimin Ding, Ziping Wang, Changli Wang, Dong Wang, Cunde Wang, Zheng Wang, Mengzhao Wang, Xiuyi Zhi, You Lu, Jifeng Feng, Yunpeng Liu, Xiaoqing Liu, Wei Liu, Gang Wu, Xiaomei Li, Kai Li, Enxiao Li, Wei Li, Gongyan Chen, Zhengtang Chen, Ping Yu, Ning Wu, Milu Wu, Wenhua Xiao, Li Zhang, Yiping Zhang, Shucai Zhang, Shujun Yang, Xia Song, Dongmei Lin, Rongcheng Luo, Li Shan, Caicun Zhou, Zongmei Zhou, Qiong Zhao, Chengping Hu, Yi Hu, Qisen Guo, Jianhua Chang, Cheng Huang, Xuan Zeng, Baohui Han, Xiaohong Han, Bo Jia, Ying Han, Yu Huang
No abstract text is available yet for this article.
February 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28134504/quality-publishing
#20
EDITORIAL
Stephen P Ackland, YuanKai Shi
No abstract text is available yet for this article.
February 2017: Asia-Pacific Journal of Clinical Oncology
journal
journal
40999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"